Champa and co-authors found that poorly differentiated and ATC cell lines, generally known to be intrinsically resistant to cell death, showed reduced tumor growth both in vitro and in vivo when treated with obatoclax, a pan-inhibitor of the anti-apoptotic proteins of the BCL2 (BCL2 apoptosis regulator) family. The gene discussed is BCL2; the disease is neoplasm.